Canaccord analyst William Plovanic lowered the firm’s price target on Edwards Lifesciences to $89 from $96 and keeps a Hold rating on the shares. The firm said they intend to keep their rating until either TAVR recovers to pre-COVID levels of growth of consistent double digits or the TMTT opportunity matures enough to bridge the difference.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EW:
- Edwards Lifesciences (NYSE:EW) Q2 Results Leave Analysts Divided; Stock Down 10%
- EDWARDS LIFESCIENCES REPORTS SECOND QUARTER RESULTS
- Edwards Lifesciences raises FY23 adj. EPS view to 2.50-$2.60 from 2.48-$2.60
- Edwards Lifesciences sees Q3 adjusted EPS 55c-61c, consensus 63c
- Edwards Lifesciences reports Q2 adjusted EPS 66c, consensus 65c